Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My position in this company means retirement, change of zip codes and adequately funding an organization that looks to place abandoned and abused children and adults with MR/DD into loving, stable environments. I continue to add as I can.
BMSN.
So, somewhere between 1 March where you said you were thinking about selling your "3 milly" and the number of times you have called this stock a POS, insisted it should be flushed, is going no where, blah, blah, blah, and today, not only did you NOT dump your shares when you said you were thinking to you have actually added 5 million shares?
That doesn't seem like investing by someone with connections deep enough to know when the FDA will render a decision. The folk the FDA let get that close are just a tad bit wiser than that. And that I know for a fact.
Just saying!
Off to get my own tissue now!
There is incredible manipulation to this stock and this is the point. The numbers are being shown for those who do not see level 2 and do not understand why they will buy 500K at 31 only to see the price go down to 30 or below in a matter of minutes.
BMSN
Figures: Same thing, 003 SELLS 0031 BUYS
0.003 999,999 14:29:06
0.003 200,000 14:22:36
0.003 47,583 14:13:54
0.0031 450,000 13:37:57
0.0031 515,000 13:28:25
0.0031 700,000 13:18:09
0.0031 100,000 13:08:52
0.003 300,000 12:28:00
0.003 4,000 12:25:32
Well, it cannot be denied that the flippers & manipulators are giving the rest of us a hard way to go. The stalemate can only last for so long, though.
Updated Buys/Sells: NOTE: the 003 are all SELLS and the 0031 are ALL BUYS. Folks aint being honest.
Trades
0.003 47,583 14:13:54
0.0031 450,000 13:37:57
0.0031 515,000 13:28:25
0.0031 700,000 13:18:09
0.0031 100,000 13:08:52
0.003 300,000 12:28:00
0.003 4,000 12:25:32
0.003 10,000 12:22:49
0.003 572,420 11:34:39
0.003 580 11:34:39
0.003 225,000 11:33:06
0.0031 26,790 11:12:58
0.0031 24,000 10:53:26
0.0031 900,000 10:50:47
0.003 23,994 10:47:54
0.003 200,000 10:40:31
0.003 10,000 10:26:12
0.003 30,000 10:24:30
0.0031 23,000 10:24:17
Updated Trades:
0.003 300,000 12:28:00
0.003 4,000 12:25:32
0.003 10,000 12:22:49
0.003 572,420 11:34:39
0.003 580 11:34:39
0.003 225,000 11:33:06
0.0031 26,790 11:12:58
0.0031 24,000 10:53:26
0.0031 900,000 10:50:47
0.003 23,994 10:47:54
0.003 200,000 10:40:31
0.003 10,000 10:26:12
0.003 30,000 10:24:30
0.0031 23,000 10:24:17
0.003 1,000,000 10:23:56
0.003 200,000 10:14:22
0.0031 300,000 10:06:59
0.0031 200,000 09:59:18
0.0031 1,280,000 09:42:45
0.0032 17,550 09:42:33
0.0031 181,070 09:30:18
0.0031 100,000 09:30:18
0.0032 14,884 09:30:18
BMSN
BMSN Trades thus far:
0.003 572,420 11:34:39
0.003 580 11:34:39
0.003 225,000 11:33:06
0.0031 26,790 11:12:58
0.0031 24,000 10:53:26
0.0031 900,000 10:50:47
0.003 23,994 10:47:54
0.003 200,000 10:40:31
0.003 10,000 10:26:12
0.003 30,000 10:24:30
0.0031 23,000 10:24:17
0.003 1,000,000 10:23:56
0.003 200,000 10:14:22
0.0031 300,000 10:06:59
0.0031 200,000 09:59:18
0.0031 1,280,000 09:42:45
0.0032 17,550 09:42:33
0.0031 181,070 09:30:18
0.0031 100,000 09:30:18
0.0032 14,884 09:30:18
RNA interference : from biology to clinical applications edited by Wei-Ping Min, Thomas Ichim.
Other Authors
Min, Wei-Ping.
Ichim, Thomas, 1976-
Published
New York : Humana Press, c2010.
Physical Description
xvi, 450 p. : ill. ; 27 cm.
Series
Methods in molecular biology, 1064-3745 ; 623.
Springer protocols.
Methods in molecular biology (Clifton, N.J.) ; v. 623.
Springer protocols
Subjects
RNA editing.
Gene silencing.
RNA Interference.
Contents
Endogenous antiviral mechanisms of RNA interference : a comparative biology perspective /? Abubaker M.E. Sidahmed and Bruce Wilkie
Monitoring innate immune recruitment by siRNAs in mammalian cells /? Michael P. Gantier and Bryan R.G. Williams
Current knowledge of microRNAs and noncoding RNAs in virus-infected cells /? Dominique L. Ouellet and Patrick Provost
Allele-specific silencing by RNA interference /? Hirohiko Hohjoh
Computational siRNA design considering alternative splicing /? Young J. Kim
Bioinformatic approaches to siRNA selection and optimization /? Pirkko Muhonen and Harry Holthofer
Optimized gene silencing by co-expression of mulitple shRNAs in a single vector /? Yasuhito Ishigaki, Akihiro Nagao, and Tsukasa Matsunaga
Stratiges in designing multigene expression units to downregulate HIV-1 /? Jane Zhang and John J. Rossi
Designing optimal siRNA based on target site accessibility /? Ivo L. Hofacker and Hakim Tafer
Chemical syntheses of 2'-O-alkylated siRNAs /? Joachim W. Engels ... [et al.]
siRNA specific delivery system for targeting dendritic cells /? Xiufen Zheng ... [et al.]
Hydrodynamic delivery protocols /? Piotr G. Rychahou and B. Mark Evers
New methods for reverse transfection with siRNA from a solid surface /? Satoshi Fujita ... [et al.]
Nonviral siRNA delivery for gene silencing in neurodegenerative diseases /? Satya Prakash, Meenakshi Malhotra, and Venkatesh Rengaswamy
Using siRNA to uncover novel oncogenic signaling pathways /? Jin-Mei Lai, Chi-Ying F. Huang, and Chang-Han Chen
12 More...
Notes
Includes bibliographical references and index.
http://trove.nla.gov.au/work/37406655?q&versionId=48777392" rel="nofollow" target="_blank" >http://trove.nla.gov.au/work/37406655?q&versionId=48777392
Incredible recent achievements in cellular and molecular biology have opened practically unlimited opportunities for the therapeutic applications of stem cells. There is little doubt that substantial financial investments and further scientific resources into the area of stem cell development will assure their practical usage in the near future.
The growing list of diseases that can be successfully cured by stem cells is expanding every day. Today, a number of malignant blood diseases have become theoretically curable due to the transplant of stem cells. Examples of such diseases are some forms of child Leucosis. It is difficult to imagine modern hematology without transplants of (hemopoetic) stem cells. The list of diseases today where such a technique is applicable exceeds 100.
-----This list includes: Rheumatoid Arthritis, Crone Disease, Multiple Sclerosis, Liver Cirrhosis, Diabetes and some drug-resistant forms of Arthritis. Oncology, as well as Breast and Lung Cancer, are other potential areas for the application of stem cells. Orthopedic practice is another area where stem cells are widely used. One of the applications here is the regeneration of large bone defects after fractures, or the regeneration of a damaged joint cartilage.
In recent years, more than 20 clinical articles have been published about the regeneration of the heart muscle after heart attacks via direct injection of stem cells and various other applications
BMSN
Reminder for those who still don't quite understand just how fast stem cell treatment is moving and how it is still being adapted to. And for those that are not sufficiently educated about where stem cells are derived for treatments.
Remember, the approach BMSN is taking is one of teaching the body to heal itself rather than using external influences that prove very toxic....
-------The below is extracted from a 2011 NIH publication written by Bobby George. Since the publication, a lot has happened with respect to implementing what is needed in order to allow a more harmonious process for those applying for IND approval. As stated, though, this is still considered very new. However, stem cell treatment is a very fast moving market and those who had little or not interest in as little as five years ago, certainly do now.
It should be noted, too, that from all that I have gathered, Regen has complied with all of the requirements and has proved that all measures required to carry out the trials from point A to point B are respected and covered.
And though a lot has changed in terms of regulatory approaches and considerations (and will continue to change no less since this is evolving at such a fast pace) the below listed data on the origin of the cells pretty much are the same.
As I have stated a number of times, we do not know when the FDA will return their decision. It can be anytime. It will be sooner than later I am pretty sure though. Contrary to what some might insist.
-------Stem cells have a unique ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Stem cell based therapies, encompassing collection, purification, manipulation, characterization delivery of cells for therapeutic purposes, have existed since the first successful bone marrow transplantation in 1968.
Presently, human embryonic stem cells (hESCs) are used in 13% of cell therapy procedures, while fetal stem cells are used in 2%, umbilical cord stem cells in 10%, and adult stem cells in majority (75%) of treatments.
There is still a significant gap between promising laboratory-based research and approved SCBPs (stem cell based products) in this fast emerging field. Legislation in this field must seek to both regulate and enable scientific progress without being confusing, difficult to interpret or unnecessarily onerous. In addition, the public must have confidence that its interests are protected. Few of the measures which could help to speed up the translation of SCBP from bench to bedside while still ensuring patient safety include the following.
In the U.S., classification of stem cell based therapies is based on indication to be treated. Restrictions are limited to research with federal funds. No limitations exist for research with hESCs, provided the funds come from private investors or specific states. The FDA has developed a regulatory framework that controls both cell- and tissue-based products, based on three general areas:
Prevention of use of contaminated tissues or cells (e.g. AIDS or hepatitis);
Prevention of inadequate handling or processing that may damage or contaminate those tissues or cells;
Clinical safety of all tissues or cells that may be processed, used for functions other than normal functions, combined with components other than tissues, or used for metabolic purposes.
Manipulated autologous cells for structural use meet the definition of somatic cell therapy products and require an “investigational new drug” (IND) exemption or the FDA license approval. In 2007, the “Guidance for Industry: Regulation of HCT/Ps – Small Entity Compliance Guide” and in 2009, the “Guidance for Industry on Current Good Tissue Practice (cGTP) and Additional Requirements for Manufacturers of HCT/Ps” had been released. Clinical studies employing mescenchymal stem cells (MSCs) underlie the IND mechanism. Accordingly, the investigators have to make an IND application, which necessitates detailed study protocols describing the clinical plan as well as the preparation and testing of the therapeutic cell product.
--Compliance with the existing regulations and guidelines to ensure that the product is safe, pure, and potent meeting GTP, GMP and GCP requirements.
--Nonclinical evidence on the proof-of-principle and safety in a relevant animal model should be tried before administration to humans.
--Encourage companies to develop and validate new non-invasive methods for biodistribution studies in humans to follow the cells during the CTs. Possible markers/tracers should be evaluated and justified.
--A risk-based approach to be applied while giving regulatory approvals. Conditional marketing authorization could be a possible approach without compromising on patient safety.
BMSN!
Though I do understand the importance of hearing the FDA have approved the IND application for HemaXellerate, that is not the most important factor. Perhaps in the short term. But there are a number of things that are playing a significant role in making this company a long-time sparkle in many deep pockets eyes.
That is what we longs are here for.
BMSN!
And which FDA approval would that be? The FDA approval of the presently submitted IND application? Or, the IND application for the cancer silencing treatment? Or the FDA approval of the RNA treatment that instructs the immune system to fight off present cancer cells? Or, the FDA approval for a number of others in the mix?
Which one? Take your pick. They all look pretty darn significant to me.
BMSN
Hit the nail on the head with that! I've mentioned that a few times to a few people!
BMSN
Dr. Min's Antitumor Immunity:
www.jimmunol.org/content/177/8/5639.full.pdf+html
A little bit of Immune Therapy and the good doc's Dr. Wei-ping Min & Dr. Thomas Ichim reading for you.
(What we are soon to witness has been in the making a while, folks):
www.tolerotech.com/research/paper_print/MAI_2005_RNAi.pdf
BMSN!
An April 2009 Wall Street Transcript interview with Dr. David Koos:
www.twst.com/?action=pdf&series=health&fileid=AMP600
Go BMSN!
(Taken from a much earlier post of mine)
Let's make this easy. Well, easily accessible. Not necessarily easy reading.
When you finish pulling your hair out trying to wrap your head around exactly what it is that Thomas Ichim, et al have been doing for many a year, be sure to read on for a wee breakdown of the challenges stem cell research has faced just from an ethical standpoint.
Then mosey on over to the next link that will provide you many links to various state laws/regulations on fetal stem cell research (appears as those has been a while since an update but I assure you you will be well educated by each link).
Then, when you're finished there, click the last link for a view of what the busy folk at wiki put together for us with respect to the SCREA.
But you'll have to go all the way back now to the origins of opposition to really understand what scientists have faced. Nothing is ever as cut and dry as you have attempted to make it seem.
When you've finished with the above, let's then discuss siRNA.
Happy reading!
www.ncbi.nlm.nih.gov/pubmed/?term=Thomas%20Ichim
www.cirm.ca.gov/about-stem-cells/myths-and-misconceptions-about-stem-cell-research
www.ncsl.org/issues-research/health/embryonic-and-fetal-research-laws.aspx
www.en.wikipedia.org/wiki/Stem_Cell_Research_Enhancement_Act
As it has been conveyed by Bio-Matrix Scientific Group from the very start--as with so many aspects of the treatments they are in the process of harnessing, their approach is NOVEL. In short, they are doing things that have never been done. And in doing so, they are setting themselves up to take a market that has so long been dictated one way, and showing that is CAN be done quite successfully in another.
A way that will prove beneficial to all those with and without a vested interest.
The below is a lot of information to digest. It goes back to what I have been saying about BMSN working to have its treatments compliment one another. And, this company consisting of a very tightly woven class of doctors who most likely have no interest at all in submitting their years of hard work, for some other entity to dictate. Not any time soon anyway. That's an opinion and an educated guess.
There are several patents being processed that represent Dr. Min's decades of work. Patents that have a promise attached to them that few people can understand. The rest of us can only speculate. And I do include myself among those though I have spent hour after hour reading & sifting.
Before I learned the required application to out fish most men, I spent many a year catching pan fish with a wee worm. As any avid fisher will tell you, patience is a must if you are going after that elusive big 'un.
Many of us have been very patient...that big 'un is within eye shot now and is has BMSN written all over it.
BMSN
(Just to remind you of what our good Dr. Min--mentor of Dr. Ichim, CSO of Regen BioPharma and respected friend & colleague of Dr. David Koos, has been perfecting a very long time.)
I do feel bad for flippers and distorter's of the truth.
Naaah, no I don't.
I am hoping my friend, Inventor, can expound upon the monumental undertakings securing patents really are. He is much more versed in this than I am. Hence, the name "Inventor".
Wee Bit of Min Here
Wee Bit of Min There
BMSN
That is exactly what I mean!!!
BMSN
Hey, PP! Yes, I have been in overdrive for a while now and will admit that I am about on the verge of being burned out. I have a few more things to complete then I am going to make a real effort to pull away for a few days.
I desperately need a mental break. But, being the OCD/ADD/Insomniac/Hypoglycemic chick that I am, I won't stop until I have completed the BMSN dd I have been working on for a while!
LOLOLOL! :-P
BMSN
As long as the line of numbers in our national debt (And, that's long Sabai, very long). But, I think you already knew that.
MEDS!
. Wow, thank you. That made my day!!! And it has been a long, long one.
I have the utmost respect for your posts. Few that they are, they speak volumes.
BMSN!
The partnership that the company is comprised of is a very tightly woven one. Stem cell therapy is only a part of what they are completing to offer the world of treatments. If they are successful in all their applications (and it certainly looks like they will be), the monetary potential of this company will far surpass anything that most consider.
Dr. Koos AND his team know this.
Selling really is of no interest to Koos.
Reduction of debt--a show of shareholder interest at heart. Ain't that something!
They can target all they like, Koos ain't selling. Well, he will be selling their science. But, he is not selling the company.
What we have just been provided by the company is proof that the CEO of Bio-Matrix Scientific Group, Dr. David Koos, has the utmost confidence in the doctors and the collective entity that have tirelessly pursued scaling every hurdle before them.
As I have said, no one, but NO ONE, contributes and sacrifices for something the way Dr. Koos has unless he has the utmost confidence in the ultimate success of the pursuit.
He KNOWS what he is doing and is DOING what he knows. As are all of his team.
The future is very close. Very close, indeed!
BMSN
I know, Paulness, things are really starting to fall into place. Great things are ahead for MEDS and all that support the company.
Have you had the opportunity to visit the below? You will find Medistem included. A great source of information here.
HCBI
MEDS
Good Morning, PP. I am all bought out this week. But maybe next. I hope your challenge is met!
BMSN
If you were supporting it, than I do apologize. That was not what I interpreted based on what you wrote.
I am very familiar with the article. And what you are suggesting is not what the article says. So perhaps that is where my confusion stems.
I know exactly who you are my conversations with the Doctors have been substantiated numerous times.
No, I am not here for the same reason as you.
BMSN!
Based on the context of your post, it appears as though you are questioning the validity of the HemXellerate treatment by attaching the link to the article and quoting the Hema overview? That is what I am getting.
Well, you just did the opposite--that article goes to further reiterate the significance of the stem cells used in the Hema treatment.
Thanks for that!
BMSN!
So what exactly is it that you are trying to infer based on what you think you have extracted from that article?
The below is extracted from a 2011 NIH publication written by Bobby George. Since the publication, a lot has happened with respect to implementing what is needed in order to allow a more harmonious process for those applying for IND approval. As stated, though, this is still considered very new. However, stem cell treatment is a very fast moving market and those who had little or not interest in as little as five years ago, certainly do now.
It should be noted, too, that from all that I have gathered, Regen has complied with all of the requirements and has proved that all measures required to carry out the trials from point A to point B are respected and covered.
And though a lot has changed in terms of regulatory approaches and considerations (and will continue to change no less since this is evolving at such a fast pace) the below listed data on the origin of the cells pretty much are the same.
As I have stated a number of times, we do not know when the FDA will return their decision. It can be anytime. It will be sooner than later I am pretty sure though. Contrary to what some might insist.
-------Stem cells have a unique ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Stem cell based therapies, encompassing collection, purification, manipulation, characterization delivery of cells for therapeutic purposes, have existed since the first successful bone marrow transplantation in 1968.
Presently, human embryonic stem cells (hESCs) are used in 13% of cell therapy procedures, while fetal stem cells are used in 2%, umbilical cord stem cells in 10%, and adult stem cells in majority (75%) of treatments.
There is still a significant gap between promising laboratory-based research and approved SCBPs (stem cell based products) in this fast emerging field. Legislation in this field must seek to both regulate and enable scientific progress without being confusing, difficult to interpret or unnecessarily onerous. In addition, the public must have confidence that its interests are protected. Few of the measures which could help to speed up the translation of SCBP from bench to bedside while still ensuring patient safety include the following.
In the U.S., classification of stem cell based therapies is based on indication to be treated. Restrictions are limited to research with federal funds. No limitations exist forresearch with hESCs, provided the funds come from private investors or specific states. The FDA has developed a regulatory framework that controls both cell- and tissue-based products, based on three general areas:
Prevention of use of contaminated tissues or cells (e.g. AIDS or hepatitis);
Prevention of inadequate handling or processing that may damage or contaminate those tissues or cells;
Clinical safety of all tissues or cells that may be processed, used for functions other than normal functions, combined with components other than tissues, or used for metabolic purposes.
Manipulated autologous cells for structural use meet the definition of somatic cell therapy products and require an “investigational new drug” (IND) exemption or the FDA license approval. In 2007, the “Guidance for Industry: Regulation of HCT/Ps – Small Entity Compliance Guide” and in 2009, the “Guidance for Industry on Current Good Tissue Practice (cGTP) and Additional Requirements for Manufacturers of HCT/Ps” had been released. Clinical studies employing mescenchymal stem cells (MSCs) underlie the IND mechanism. Accordingly, the investigators have to make an IND application, which necessitates detailed study protocols describing the clinical plan as well as the preparation and testing of the therapeutic cell product.
--Compliance with the existing regulations and guidelines to ensure that the product is safe, pure, and potent meeting GTP, GMP and GCP requirements.
--Nonclinical evidence on the proof-of-principle and safety in a relevant animal model should be tried before administration to humans.
--Encourage companies to develop and validate new non-invasive methods for biodistribution studies in humans to follow the cells during the CTs. Possible markers/tracers should be evaluated and justified.
--A risk-based approach to be applied while giving regulatory approvals. Conditional marketing authorization could be a possible approach without compromising on patient safety.
BMSN!